The following data and parameters were monitored: age,sex, family history, data on smoking and alcohol consumption, BMI (body mass index), blood pressure, blood glucose, total cholesterol, triglycerides, LDL, HDL, fibrinogen, uric acid. MASCC risk-index score, which was originally developed to identify low-risk patients, in turn showed that the lower the MASCC score, the poorer the prognosis of febrile neutropenia, with very low levels ( 7% were considered to have poorly controlled diabetes. Hematological parameters, prophylactic measurements and patient-specific risk factors showed inconsistent results. Various prognostic factors have been suggested with controversies.

The authors reviewed recent literature to provide an update on research regarding predictive factors for poor prognosis in patients with febrile neutropenia. However, even in low-risk patients, medical complications including bacteremia could happen. Recent developments of risk stratification enabled early discharge with oral antibiotics for low-risk patients. However, it still remains a life-threatening treatment-related toxicity, and is associated with dose reductions and delays of chemotherapeutic agents that may compromise treatment outcomes. Most patients with chemotherapy-induced febrile neutropenia recover rapidly without serious complications. Predictive factors for poor prognosis febrile neutropenia. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (1 line of induction and lack of maintenance.

We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. Kumar, S K Dispenzieri, A Fraser, R Mingwei, F Akpek, G Cornell, R Kharfan-Dabaja, M Freytes, C Hashmi, S Hildebrandt, G Holmberg, L Kyle, R Lazarus, H Lee, C Mikhael, J Nishihori, T Tay, J Usmani, S Vesole, D Vij, R Wirk, B Krishnan, A Gasparetto, C Mark, T Nieto, Y Hari, P D'Souza, Aĭuration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Ekaterina velika serial